Global Oncology Partnering Report 2012-2018: Updated Deal Trends, Players and Financials Analysis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Global Oncology Partnering 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.
The Global Oncology Partnering 2012-2018: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the world’s leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Oncology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Oncology deals.
The report presents financial deal terms values for Oncology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scopeTrends in oncology dealmaking in the biopharma industry since 2012 Analysis of oncology deal structure Access to headline, upfront, milestone and royalty data Access to over 3,500 oncology deal records The leading oncology deals by value since 2012
Available deals are listed by:Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Oncology dealmaking
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication
Chapter 3 -Financial deal terms for Oncology partnering
3.2. Disclosed financials terms for Oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates
Chapter 4 - Leading Oncology deals and dealmakers
4.2. Most active in Oncology partnering
4.3. List of most active dealmakers in Oncology
4.4. Top Oncology deals by value
Chapter 5 - Oncology contract document directory
5.2. Oncology partnering deals where contract document available
Chapter 6 - Oncology dealmaking by therapeutic target
6.2. Deals by Oncology therapeutic target
Appendix 1 - Directory of Oncology deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Oncology deals by deal type 2012 to 2018
Appendix 3 - Directory of Oncology deals by stage of development 2012 to 2018
Appendix 4 - Directory of Oncology deals by technology type 2012 to 2018For more information about this report visit https://www.researchandmarkets.com/research/d8dwdv/global_oncology?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005878/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/25/2018 11:18 AM/DISC: 09/25/2018 11:18 AM